Drug Search Results

Pelitinib

Alternative Names: pelitinib, ekb-569
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pelitinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colorectal Cancer|Non-Small-Cell Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial	Phase	Trial Status	Disease	Primary Completion Date
NCI-2012-01459	P1	Completed	Oncology Solid Tumor Unspecified	2007-10-01
3095A1-201	P2	Completed	Non-Small-Cell Lung Cancer	2005-01-01
3095A1-200	P2	Completed	Colorectal Cancer	2004-10-01

Recent News Events

Date	Type	Title
04/01/2024	PubMed	An allosteric mechanism for potent inhibition of SARS-CoV-2 main proteinase.
09/21/2023	PubMed	The construction of a prognostic model of cervical cancer based on four immune-related LncRNAs and an exploration of the correlations between the model and oxidative stress.
08/01/2023	PubMed	Ex vivo and In vitro antiplasmodial activities of approved drugs predicted to have antimalarial activities using chemogenomics and drug repositioning approach.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions